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ABSTRACT
The pharmacokinetics of the Cl 10 anti-carcinoembryonic antigen an
tibody radiolabeled with '"In via a novel benzylisothiocyanate derivative
of diethylenetriamine pentaacetic acid have been determined in 12 pa
tients. The chelator was attached to the protein via a thiourea bond and
in such a way that all 5 carboxymethyl arms were presumably able to
participate in chelation. Patients with known or suspected colorectal
carcinoma received between 5 and 20 mg of the IgG antibody labeled
with5 niCi of '"In. Individual organ radioactivity levels werequantitated,
and serum and urine samples were analyzed, principally by size exclusion
high-performance liquid chromatography (HPLC). Total urinary excre
tion averaged 0.18% of the injected dose/h with large patient to patient
variation. At early times postadministration (<8 h) the predominant
radiolabeled species in urine was free diethylenetriamine pentaacetic acid
most probably administered as a small radiocontaminant in the injectate.
Thereafter, radioactivity in urine was primarily present as a low molecular
weight catabolic product. Analysis of serum by size exclusion HPLC
occasionally showed 3 radioactivity peaks, 2 of which are due to circu
lating immune complexes and labeled antibody. The third peak is of low
molecular weight and is due to one or more products of antibody catab-
olism. Transchelation of '"In to circulating transferrin was observed but
at modest levels. Quantitation of organ radioactivity showed that 18 Â±4
(SI ))'/â€¢;of the injected dose was in the liver at 1 day postadministration
and 1.4 Â±1.1 and 1.2 Â±0.9% was in the spleen and in both kidneys,
respectively, at this time. The mean half-life for clearance of total injected
radioactivity was fitted to a single exponential and was found to be 34 h
(SD, 14 li: .V= M )and that for antibody alone, assessed by size exclusion
HPLC analysis of serum samples, was calculated to be 22 h (SD, X li; V
= 10). Neither of these values nor organ radioactivity levels were affected
by antibody-loading dose.
INTRODUCTION
A derivative of the bifunctional chelator DTPA1 has recently
been synthesized in which a p-isothiocyanatobenzyl moiety is
attached to a mÃ©thylÃ¨necarbon atom on one of the carboxy
methyl arms (1). This chelator was intended to be covalently
conjugated to antibodies as a means of radiolabeling these
proteins with '"In (2). At present, the method most often used
for this purpose attaches DTPA through either its mixed (3) or
cyclic anhydrides (4). There are at least 2 major differences in
this new approach to labeling antibodies: (a) whereas both
anhydrides conjugate DTPA via amide bonds, the new chelator
Received 4/9/90; accepted 8/20/90.
The costs of publication of this article were defrayed in part by the payment
of page charges. This article must therefore be hereby marked advertisement in
accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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North, Worcester. MA 01655.
3The abbreviations used are: DTPA, diethylenetriamine pentaacetic acid;
CEA, carcinoembryonic antigen; HPLC. high performance liquid chromatogra
phy; ID. injected dose; BSA. bovine serum albumin; PBS. phosphate-buffered
saline; HAMA, human anti-mouse antibody.
is conjugated via a thiourea bond, and (b) when attached via its
anhydrides, DTPA is conjugated through one of its carboxy
methyl arms which may not then be available to participate in
chelation of indium. By contrast, conjugation of the new che
lator preserves all 5 carboxymethyl arms. It has been suggested
that all 5 arms are necessary for the stable chelation of indium
(5, 6).
The object of this investigation was to evaluate the pharma
cokinetics in patients of one antibody conjugated with the new
chelator and radiolabeled with '"In. The antibody selected for
this study was the anti-CEA Cl 10 developed by Sumerdon et
al. (2). For this investigation, the intact IgG antibody was
conjugated with an average of 6 chelators/protein molecule and
radiolabeled with '"In. "'In, 5 mCi, and the antibody, between
5 and 20 mg, were administered to 12 patients with documented
or suspected colorectal carcinoma. In this report we describe
the pharmacokinetic behavior of the label; a detailed description
of the imaging results obtained in these patients will appear
elsewhere.4
MATERIALS AND METHODS
The C110-DTPA antibody-chelator conjugate, prepared and char
acterized as previously described (2), was supplied by Abbott Labora
tories as a sterile, apyrogenic solution in 0.05 M citrate buffer, pH 6, at
a concentration of 5 mg/ml.
The conjugated antibody was radiolabeled with carrier-free "'In
(NEN Dupont, Billerica, MA) by adding 5 mCi of this activity to the
desired weight of antibody. The labeled antibody preparation was
assayed by size exclusion HPLC using a single 7.5 x 300-mm TSK 250
column (BioRad Laboratories, Richmond, CA) or a single 10 x 300-
mm SuperÃ³se 12 column (Pharmacia, Piscataway, NJ) and 0.05 M
phosphate buffer, pH 7.0, eluant. The output of an in-line radioactivity
detector was digitized and stored in a multichannel analyzer to facilitate
the calculation of peak areas (7). Recovery was determined by counting
the effluent against a standard of the injectate.
Patients enrolled in this investigation gave informed consent and
were studied with the approval of the Food and Drug Administration
(IND BB 2732) and the appropriate institutional review committees.
Each patient received 5 mCi and either 5, 10, or 20 mg of the labeled
antibody in 180 ml of normal saline for injection by slow infusion (10
ml/min) into a peripheral vein. One preadministration and several
postadministration blood samples were collected over 3-4 days in red-
top Vacutainers so that serum would be available after clotting. A
complete urine collection over the same period was also obtained.
Regular whole body and spot images were obtained for patients 1-9 on
an Ohio-Nuclear LFOV gamma camera and for subsequent patients on
a Seimens Body Scan. Attenuation correction was achieved as previ
ously described (8).
Several blood samples were collected in heparinized tubes so that the
percentage of radioactivity bound to formed elements could be deter
mined.
4 T. W. Griffin, A. B. Brill, J. A. Collins, et al. Initial clinical study of indium-
111 labeled clone 110 anti-CEA antibody in patients with colorectal cancer. J.
Clin. Oncol.. submitted for publication.
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For most patients, 3-5 serum samples were analyzed by size exclu
sion HPLC using a single 7.5 x 300-mm TSK 400 column (BioRad) or
a single 10 x 300-mm SuperÃ³se 12 column (Pharmacia) with 0.05 M
phosphate buffer, pH 7.0, eluant. Serum samples were analyzed sem-
iautomatically using a WISP injector (Waters Associates, Milford, MA)
and an automatic fraction collector. Fractions were then counted in an
automatic well gamma counter. In addition to the analysis of serum
samples by size exclusion, sera from the first 4 patients were also
analyzed by cation exchange HPLC using a single 7.5 x 75-mm SP
5PW column (Waters) with gradient elution from 0.02 M sodium
acetate, pH 5.0, to 0.5 M sodium sulfate, 0.02 M Tris hydrochloride,
pH 8.0, in 30 min. Urine samples from the first 5 patients were analyzed
both by open column Sephadex G25 chromatography and by size
exclusion HPLC using a single 7.5 x 300-mm 1-60 column (Waters)
and 0.05 M phosphate buffer, pH 7.O. Urine samples from subsequent
patients were analyzed by size exclusion HPLC using the SuperÃ³se 12
column and by aniÃ³n exchange HPLC using a 7.5 x 75-mm DEAE
column (Waters) with gradient elution from 0.02 MTris buffer, pH 8.5,
to 0.02 M Tris buffer, 0.5 M sodium chloride, pH 7.0. in 30 min.
Regardless of the method of analysis for both serum and urine samples,
the in-line radiation detectors were too insensitive to record radioactiv
ity levels so that fractions (0.2-0.8 ml) were collected for counting in a
well gamma counter.
Radioactivity levels in all serum and urine samples were also deter
mined by counting an aliquot of each sample in a well gamma counter.
In a limited number of analyses, the percentage of serum radioactivity
present as labeled antibody, immune complex, and occasionally as
catabolic product(s) could be determined. In these cases, the SAAM29
computer program (9) was used to estimate serum clearance curves for
each species separately. Because of the larger number of reliable meas
urements of antibody concentration, this analysis was most successful
when applied to this species.
The determination of the rate and extent of transcomplexation of
'"In from antibody in circulation to transferrin was achieved by goat
anti-human transferrin affinity chromatography as described previously
(10). The percentage of serum activity binding to the column is propor
tional to the concentration of '"In-labeled transferrin in the sample.
Serum samples obtained at between 14 and 210 days after antibody
administration were also analyzed for HAMA. To each of several test
tubes, 1 polyethylene bead (Precision Plastic Ball Co.. Chicago. IL)
previously coated with a mouse antibody (19-9; Centocor. MÃ¤hern,
PA) was added along with 300 p\ of bicarbonate buffer, pH 9.6.
containing \c/c human serum albumin. The beads were incubated for 1
h at 37Â°Cand were then washed 2 times with PBS containing 1%
human serum albumin and 0.05/c Tween 20. A sample of a patient's
serum with a known titer of anti-mouse antibody was used as a standard.
Three hundred n\ of the control sera (1:5 serial dilutions in PBS) and
the sera under investigation (diluted 1:4 in PBS) were added to separate
test tubes containing the washed beads. The test tubes containing the
beads were agitated on a laboratory rocker at room temperature for 1.5
h. The beads were then washed with PBS/Tween 20, and the tracer.
"'In-DTPA-OC-125 F(ab')2, at 50 ng/ml, was added. The beads were
incubated for 16 h at room temperature and were then washed as before
and counted in a well gamma counter.
RESULTS
The results of all tests to which the antibody was subjected,
both before and after coupling and labeling, demonstrated that
the injectate was safe for human use. Thus, the preparation was
shown to be sterile, apyrogenic, and free of murine retroviruses,
Mycoplasma, and potential toxic substances (Quality Biologies,
Camden, NJ). Two preparations of conjugated Cl 10 antibodies
were used in this investigation; patients 1-9 received antibody
from the first lot, while the remaining patients received antibody
from the second. The average number of chelator groups per
antibody molecule was 6 for both lots. Despite this relatively
high degree of conjugation, the immunoreactivity of the anti
body was unaffected (2).
Following radiolabeling, analysis by size exclusion HPLC
showed that 96% (SD, 4%; N = 13) of the label was bound to
antibody. The recovery during these analyses averaged 93%
(SD, 4%;7V = 13).
Twelve patients were enrolled in this study, each with docu
mented colorectal carcinoma. The median age was 54 years,
with a range of 36-71 years. Six patients received 5 mg, 5
received 10 mg, and 2 received 20 mg. The first patient received
5 mg of the labeled antibody preparation and 15 months later
received a second administration of 10 mg. Table 1 identifies
patients by number and lists the preinjection circulating CEA
levels, antibody dose administered, the percentage of adminis
tered dose in the liver at 1 day, and the percentage of radioac
tivity in serum present as immune complex at approximately 1
day postadministration.
Organ Quantitation. The time-dependent radioactivity levels
in liver are plotted in Fig. 1 with each patient identified by-
number. In most cases, liver accumulation of label is consistent
with that observed in this laboratory for 2 other antibodies
labeled with "'In (8, 10). Maximum values are reached imme
diately, with blood pool activity contributing significantly to
the earliest measurement. Thereafter, high values persist
throughout each investigation (not shown in Fig. 1 is a value
for patient 3 of 16% ID in the liver at 142 h). Excluding patients4 and 1*(second study of patient 1), the mean liver radioactivity
level at 1 day postadministration is 18% (4% SD, N= 9).
Mean values for spleen uptake of radiolabel at approximately
1 day postadministration was 1.2% (SD, 1.1%; N = 13) and for
both kidneys was 1.4% (SD, 0.9%; N = 13). As in the liver,
spleen and kidney radioactivity levels were generally unchanged
throughout each investigation.
Urine Analysis. Release of radioactivity to urine was slow but
steady in all patients, averaging 0.18% ID/h (SD, 0.08%; N =
13), a value which is less than that observed by us for 2 other
antibodies (8, 10). Fig. 2 presents urine radioactivity in per
centage of injected dose (corrected for decay) present in each
collection plotted at the middle of the collection period. Pre
sented in this manner, it is clear that release of radioactivity
into urine goes through a pronounced minimum at about 8 h
postadministration.
Chromatography by G25 open column and 1-60 HPLC
showed that radioactivity in urine Ã©lÃ»tespredominantly in one
peak. Size exclusion HPLC analysis using the SuperÃ³se 12
Table t Antibody uose, preadministration circulating CEA antigen let-els,
percentage of serum activity present as immune complex, and percentage of
administered activity in liver, at approximately I day postadministration
Listed separately by patient.
Patient123456789101112,.Â»Prcadministration
Dose CEA levels
(mg)(ng/ml)555101010102020555102411145254620565328499303150.6684Immune
complex
at 20-29 h(%)9(I266.1(16Id8231334770Liver
activity
at 19-29h
(%ID)18142070M 22141412262l61
' Not available.
' 1*. second administration to patient
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10 20 30 40 50 60
Time (hrs)
70 80
Fig. 1. Radioactivity in liver presented as percentage of administered '"In
(corrected for decay) compared with time after administration of labeled antibody.
Patients identified by number.
column showed a slight difference in retention time of this
prominent peak between early and late urine collections. The
resolution was improved by aniÃ³n exchange DEAE HPLC
analysis, and radiochromatograms obtained of a mixture of
urine collected from one patient at 0-4 and 24-48 h showed 2
distinct peaks. The first was exclusively present in an identical
analysis of the 0- to 4-h urine collection, while the second was
alone in the 24- to 48-h urine collection. This behavior is similar
to that observed by us previously in clinical trials with the 19-
9 and OC-125 antibodies radiolabeled with '"In via the cyclic
anhydride of DTPA. At early times, radioactivity in urine was
primarily due to radiolabeled free DTPA clearing to urine
following its introduction into serum as a small radiocontami-
nant of the injectate. At later times, however, this chelate was
no longer observed in urine. Instead, the predominant species
in late urines, while also of low molecular weight, no longer
coeluted with labeled DTPA and was a product of antibody
catabolism (8, 10).
Accumulations of '"In activity in the gastrointestinal tract
was occasionally seen in late images.
Serum Analysis. Figs. 3 and 4 show the individual serum
levels of total radioactivity for each patient identified by num
ber. As seen best in Fig. 3, in almost every case a transient
increase in serum radioactivity occurred at 15 min to 2 h
postadministration. Since the initial time point in these figures
is 15-30 min after the start of antibody infusion, the maximum
is unlikely to be due simply to buildup of serum activity during
a slow infusion. Furthermore, serum samples were removed
from the arm contralateral to that receiving the infÃºsate; thus
this behavior cannot be attributed simply to contamination.
Size exclusion HPLC was performed on a total of 67 serum
samples from the 12 patients. Serum samples from the first 10
patients were analyzed on a TSK 250 column (BioRad), while
serum from later patients was analyzed on a SuperÃ³se 12
column (Pharmacia). The radiochromatograms most often
show a prominent peak corresponding to that of labeled anti
body. However, species with both shorter and longer retention
times were occasionally observed. Fig. 5 shows the most pro
nounced example of a radiochromatogram in which all 3 species
are apparent. The radiochromatogram was obtained by analysis
of the 24-h serum from patient 4. In this case the first peak
(shortest retention time) predominates and is due to immune
complexes resulting from high circulating CEA levels (Table
1). The second peak coelutes with the labeled antibody and is
therefore at least largely due to radiolabeled antibody still
present in serum. The third peak (longest retention time) coe
lutes in this analysis with radiolabeled DTPA. However, radi
olabeled DTPA. administered as a small radiocontaminant in
the injectate, may be expected to clear rapidly into urine from
serum by glomerular filtration. Since this peak was observed
only in sera collected after about 20 h postadministration, it is
likely that the species responsible is not labeled DTPA but is a
catabolic product with a similar retention time by size exclusion
HPLC.
The analysis of each serum sample by size exclusion HPLC
and under the assumption that each peak was due to a single
radiolabeled species resulted in estimates for the fraction of
radioactivity in serum present in each of 3 species. An attempt
10 60 7020 30 40 50
Time (hrs)
Fig. 2. Radioactivity in urine presented as a percentage of administered 'In
(corrected for decay) compared Â«ith time after administration and plotted at the
mean of each collection period. Patients identified by number.
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Fig. 3. Radioactivity in serum presented as a percentage of administered '"In
(corrected for decay)/ml compared with time after administration. Patients iden
tified by number. Only early time points (0-7 h) are presented.
was made to determine separate serum clearance curves for
each of the 3 species. However, in most patients the immune
complex was increasing or constant throughout the sampling
period rather than clearing. Likewise, an estimation of clearance
of the low molecular weight species was restricted by a paucity
of data points especially in the later samples. Only in the case
of the antibody itself was there a sufficient sample size for an
accurate determination. Therefore, Table 2 lists, by patient, the
pharmacokinetic values for the antibody alone. Furthermore,
the antibody clearance half-life has been calculated by fitting to
a single exponential correlation coefficient (P > 0.97). To have
assumed two compartments would have required that the initial
half-life of clearance be determined on the basis of one (the
initial) serum value for labeled antibody. The values for patients
2, 4, and 5 have been excluded from this analysis because of
limited data points. Also in the table are listed the plasma
volume for each patient calculated by height and weight and
the initial volume of distribution. The initial volume of distri
bution was determined by fitting serum concentration curve
with a sum of two or three exponentials, as needed, and then
computing the value of the fitting function. The initial volume
of distribution is then given by the radioactivity administered
divided by the fitting function evaluated for t = 0. A more
detailed description of pharmacokinetic modeling applied to
the results of this investigation may be found elsewhere.5
A search for correlation was performed among antibody dose,
preinjection CEA levels, organ uptake, immune complex, and
catabolic species formation. Possibly because of the limited
dose range (5-20 mg) and the limited number of patients at
each dose, no correlation was apparent for most parameters.
The sole exception was the relationship between preinjection
CEA levels and the rate of formation of immune complex. The
rate of formation was determined by the method of Beck and
Rescigno (11) and was found to be directly proportional to
CEA level.
The extent of transcomplexation of the label from antibody
to transferrin was first investigated by cation exchange HPLC.
In a previous study of the OC-125 antibody, this Chromato
graphie system was used to identify the presence of circulating
"'In-labeled transferrin and to estimate its concentration (10).
In this study an identical analysis of serum from a patient who
received 5 mg of antibody showed no evidence of labeled
transferrin. Furthermore, a similar negative result was obtained
using immunoprecipitation and electrophoresis with autoradi-
ography.4 Consequently, in subsequent studies, an anti-human
transferrin affinity column was used (10). In this way, the mean
transcomplexation rate was found to be 3.3%/day (SD, 2.8%/
day; N = 7) in patients receiving 10-20 mg of antibody. This
value is lower than that observed earlier by us (8, 10) of about
9%/day for other antibodies labeled with '"In after conjugation
with DTPA. In our previous studies, only 1 mg of antibody was
administered to each patient and the antibody was conjugated
with only an average of 1 chelator/molecule. In the present
study of the Cl 10 antibody, up to 20 mg was infused and an
average of 6 chelators were attached. Thus the possibility was
0.05
0.0
50 60 70 80
Time (hrs)
Fig. 4. Radioactivity in serum presented as a percentage of administered '"In
5A. Rescigno. H. Bushe. A. B. Brill, el al. Pharmacokinetic modeling of ami- (corrected for dccay)/ml compared with time after administration. Patients iden-
CEA antibody distribution in man. Am. J. Physiol. Imaging, in press. tified by number. All time points (0-80 h) are presented.
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considered that the transchelation rate may depend on chelator
concentration. Accordingly, in vitro 37Â°Cserum incubations
were performed at two different concentrations of labeled Cl 10
antibody. The results are shown in Table 3. When the chelator
concentration in serum was adjusted to be roughly equal to that
of our previous patient studies (5 ng/ml), the transchelation
rate was found to be approximately 5%/day. However, when
the concentration was increased a factor of 25, the rate dropped
to approximately 2%/day. The 5%/day value for transchelation
obtained by in vitro incubation may be compared to the 9%/
day value observed by us previously. The fact that the former
rate is lower indicates that the chelator used in this study forms
a chelate which is more stable to transchelation of '"In to
transferrin.
IO
^->
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o
o
0Â°OoI>o<>ooo(>0<>o'>oOOo000oooooooo000ooOo
10 20 50 60 70 8030 40
FRACTION
Fig. 5. Radiochromatogram obtained by size exclusion HPLC analysis of
serum collected at 1 day postadministration of '"In-labeled C110 antibody to
patient 4. The 3 peaks have been identified as immune complexes (shortest
retention time), labeled antibody, and catabolic product(s).
Table 2 Antibody and total radioactivity terminal serum half-lives assuming a
single compartment clearance, the initial volume of distribution of antibody and
of total radioactivity, and the plasma volume of distribution based on height
and Â»'eight
Listed separately by patient.
Patient123456789101112,.Â»MeanSDAntibody
terminal
half-life
(h)3 .9* 9.4a*27.122.618.724.035.09.625.48.222.28.2Total
radioactivity
terminal
half-life(h)36.837.028.826.025.634.835.634.237.646.611.137.08.333.813.8Antibody
initial
volume
(liters)2.2â€¢2.5*â€¢2.63.23.82.49.62.02.01.4Total
radioactivity
volume
(liters)2. 3.23.82.72.93.73.02.12.43.32.22.63.6Plasma
volume
(liters)2 3 23 3 12 13 3 2 22.43.33.32.72.4
Â°Excluded.
'' 1*. second administration to patient 1.
Table 3 Rates of transchelalion of'"In from CI 10 antibody to transferrin, N = 5
Relative chelator
concentration125T=01.6
Â±0.4Â°
1.1 Â±0.2
Not significant7"=48h11.0
Â±3.94.7
Â±1.2
P < 0.01
'% of activity Â±SD.
With the exception of the second administration to patient
1, all preinjection serums showed no evidence of HAMA activ
ity (i.e., HAMA levels of <30 ng/ml). Postadministration
HAMA levels were determined once for each patient (with the
exception of patients 9 and 11) on sera collected between 14
and 205 days. Patients 2, 4, 5, 7, 10, and 12 were negative for
HAMA (i.e., titers of <80 ng/ml). The remaining patients
showed HAMA titers of 140-8250 ng/ml and are therefore all
considered positive. These results are in general agreement with
a more complete analysis of anti-isotype and anti-idiotype
HAMA titers.6
Formed Element Binding. The binding of radioactivity to
formed elements in blood was determined at several time points
in 5 patients and in in vitro incubations in which the labeled
antibody was added to normal blood at a concentration of 1
Mg/ml. Analysis was by centrifugation and counting of the
packed cells and platelets after multiple rinses with cold saline.
At approximately 2 days postinjection 4.7% (SD, 4.3%; N = 5)
of radioactivity in blood was bound to formed elements. Using
differential centrifugation (12), we determined that almost all
this radioactivity was on RBCs.
Patient Imaging. The image presented in Fig. 6 is typical of
those obtained in this investigation. Shown is a posterior whole
body image obtained 22 h postadministration of 20 mg of
labeled antibody (patient 8). Activity is present in kidneys and
liver and, to a lesser extent, in bone marrow. An intense focal
lesion appears in the pelvis that is suspected of being due to
metastatic colorectal cancer from a primary removed surgically
3 months previously. A detailed description of the imaging
results obtained in these patients will appear elsewhere.4
DISCUSSION
This laboratory has conducted 2 previous pharmacokinetic
investigations of antibodies in patients with the 19-9 (8) and
the OC-125 antibodies (10) radiolabeled with '"In. A compar
ison of these results with that obtained in the present study is
inexact even though all 3 antibodies are of the IgGl isotype
because the 19-9 and OC-125 antibodies were administered as
the F(ab')2 fragment, while the C110 was used as the intact
IgG. Furthermore, only 1 mg of 19-9 and OC-125 antibody
was administered, whereas between 5 and 20 mg of Cl 10 was
used. A final significant difference is the chelator used. Whereas
the 19-9 and OC-125 antibodies were both conjugated with
DTPA using the cyclic anhydride, in the present study a deriv
ative of DTPA was attached. Nevertheless, some similarities
are apparent.
The level of radioactivity in the liver was similar in all 3
studies (18, 20, and 12% ID for the Cl 10, 19-9, and OC-125,
respectively, at 24 h). However, a higher liver level may be
expected for the intact Cl 10 antibody over that of the F(ab')2
fragments since Fc receptors in the liver are thought to contrib
ute to the accumulation of IgG antibodies in this organ (13).
Furthermore, it may have been anticipated that liver levels in
this investigation would have been low (and possibly decreasing)
judging from the favorable results obtained in mice with anti
bodies radiolabeled with '"In via an isothiocyanatobenzyl
DTPA chelator (5). It has been suggested that the decreased
liver levels observed in animals may be due to dissociation of
* R. J. Kinders, S. Stevens, G. M. Hass, J. Daufeldt. J. Jennings. J. Pennoyer.
A. Boghosian. and T. W. Griffin. Human immune response to the anti-CEA
murine monoclonal antibody C'110 in a phase I clinical trial, manuscript in
preparation.
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Fig. 6. A posterior whole body image obtained at 22 h after the administration
of'"In-labeled Cl 10 antibody to patient 8. In addition to activity in the kidneys,
liver, and bone marrow, an intense focal lesion is evident in suspected metastatic
colorectal cancer in the pelvis.
the thiourea bond with the release from the liver of the intact
chelate (14). If so, it is likely that the extent of this phenomena
may be limited in patients such that liver levels are not greatly-
affected (15).
Particularly high liver radioactivity levels were observed inpatients 4 and 1' (Table 1). The exceptionally high liver levels
observed in the case of patient 4 are most likely due to antigen-
antibody immune complex formation resulting from a high
circulating CEA level with clearance into the liver. Size exclu
sion HPLC radiochromatograms show that a high molecular
weight species formed in serum immediately upon antibody
administration and persisted as the predominant species
throughout this investigation. It is interesting that spleen and
kidney levels were unremarkable in this case (0.6 and 0.4%,
respectively, at 24 h). The explanation for the high liver levels
obtained in the second administration to patient 1 may also be
the elevated CEA levels, although, in this case, the high liver
levels (and the rapidly clearing serum radioactivity) may be due
to a HAMA response resulting from the first injection of the
C110 antibody to this patient 15 months previously. A serum
sample from this patient obtained 7 months after the first
antibody administration showed mildly elevated HAMA levels
by two assays. The size exclusion HPLC radiochromatograms
show that a high molecular weight peak appeared in serum
within l h of the second antibody administration and became
the predominant species at 20 h. These 2 cases illustrate the
profound effect that immune complex formation can have on
biodistribution.
The analysis of serum and urine samples in this investigation
showed patterns which had been previously observed in the case
of the 19-9 and OC-125 antibodies. A catabolic radiolabeled
species with a molecular weight similar to that of labeled free
DTPA appears in urine after approximately 8 h. It is likely that
this species is generated in the liver since patient 4 exhibited
levels among the highest urine levels and also had the highest
level of radioactivity in liver (Fig. 1).
An important feature of this investigation was the determi
nation of the number and concentrations of radiolabeled species
in a large number of patient sera. As a result, it was possible to
determine the half-life for clearance and the volume of distri
bution for the radiolabeled antibody itself rather than for the
mixture of radiolabeled species which makes up the total serum
radioactivity. Since these analyses showed that radiolabeled
antibody was often the predominant species, the concentration
of this species was determined with more certainty than that of
the immune complex or catabolite especially in late samples.
Because of physical decay and biological clearance, the counting
rates of fractions obtained by HPLC analysis of these late
samples were often close to the limit of detection. As such only
values for the radiolabeled antibody are presented in Table 2.
It is apparent from the table that, under the assumption of
single compartment clearance, the terminal clearance half-time
varied over a considerable range from patient to patient.
The volumes of distribution at steady state are not reported
because of uncertainties in these values even in the case of
radiolabeled antibodies. The error inherent in estimating the
area under the clearance curve out to steady state became
unmanageable due to low radioactivity levels in late serum
samples. The initial volume of distribution for the antibody are
more useful, although also subject to uncertainty, in this case
because the antibody was administered by slow infusion, and
thus the initial collection times are not well defined.
Based on the results presented in Table 2, the terminal
clearance half-time for the antibody is 22 h. When the identical
analysis is performed on the total serum radioactivity, this value
becomes 34 h. The significant difference (P < 0.02) in these
values may reflect the contribution to total radioactivity clear
ance of other species, especially immune complexes. The longer
clearance half-life found for total radioactivity over that of
antibody itself reflects the fact that immune complexes and
catabolites were accumulating in blood during the observation
period. As expected, the plasma volumes calculated by height
and weight and the initial volumes of distribution are in good
agreement, especially for total radioactivity.
One surprising result of this investigation is the lack of
influence of antibody dose on pharmacokinetics. Other inves
tigators have reported decreasing liver accumulation and de
creased serum clearance with increasing antibody dose. How-
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ever these previous studies involved higher antibody doses and
covered a larger range (16, 17).
The image presented in Fig. 6 illustrates some of the phar-
macokinetic behavior of the C110 antibody; activity levels in
blood pool are low at 22 h postadministration, and activity has
accumulated in normal organs such as kidneys, liver, bone
marrow, and spleen. Nevertheless, the image also shows striking
accumulation of label in one suspected lesion in the pelvis. This
accumulation demonstrates that the C110 antibody possesses
interesting properties for imaging CEA-expressing tumors and
that the method of labeling used in this investigation provides
a useful alternative to standard methods of radiolabeling.
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